ストックスクリーナーアプリを入手
3.30
0.60%
-0.02
アフターアワーズ：
3.31
0.01
+0.30%
前日終値:
$3.32
開ける：
$3.44
24時間の取引高:
38,664
Relative Volume:
0.09
時価総額：
$2.14M
収益：
$104.00K
当期純損益:
$-8.39M
株価収益率:
-0.0317
EPS:
-103.9477
ネットキャッシュフロー:
$-8.31M
1週間 パフォーマンス:
-17.50%
1か月 パフォーマンス:
+0.90%
6か月 パフォーマンス:
-90.28%
1年 パフォーマンス:
-95.63%
1日の値動き範囲:
$3.26
$3.4585
1週間の範囲:
$3.255
$4.06
52週間の値動き範囲:
$2.86
$96.50
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Compare BDRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
3.30 | 2.15M | 104.00K | -8.39M | -8.31M | -103.95 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-08 | 開始されました | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr (BDRX) 最新ニュース
BDRX Stock Price, Quote & Chart | BIODEXA PHARMACEUTICALS-ADR (NASDAQ:BDRX) - ChartMill
Inventory turnover of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Net income before discontinued operations of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Book value per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView — Track All Markets
Biodexa Pharmaceuticals plc Sponsored ADR Cash Flow – FWB:5MP2 - TradingView — Track All Markets
Net debt of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Basic earnings per share (basic EPS) of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Price to earnings ratio of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP2 - TradingView
Who's Buying or Selling Biodexa Pharmaceuticals PLC (STU:5MP2) Stock Today? - GuruFocus
Biodexa Pharmaceuticals Plc: Shareholders Board Members Managers and Company Profile | US59564R8723 - marketscreener.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today? - Sahm
Why is Biodexa Pharmaceuticals (BDRX) stock skyrocketing today? - MSN
Biodexa partners with Syngene for MTX240 manufacturing By Investing.com - Investing.com Australia
171.7M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - Stock Titan
109.8M Ordinary Shares resale prospectus — Biodexa (NASDAQ: BDRX) - stocktitan.net
943.4M Ordinary Shares for Resale; Biodexa (NASDAQ: BDRX) resale filing - stocktitan.net
1.7018B shares for resale by holders — Biodexa (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADS for resale via equity line - Stock Titan
Biodexa’s eRapa Program: Global Expansion and European Gains - StocksToTrade
Biodexa partners with Syngene for MTX240 manufacturing - Investing.com
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies - ChartMill
BDRX SEC FilingsBiodexa Pharmaceuticals plc 10-K, 10-Q, 8-K Forms - Stock Titan
Weeks after Otsuka license, Biodexa secures MTX240 trial manufacturing - Stock Titan
No approved FAP drug: Biodexa opens global eRapa access - Stock Titan
[EFFECT] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) registers 2.99M ADSs for resale under equity line - Stock Titan
943.4M Ordinary Shares resale by selling holders (NASDAQ: BDRX) - Stock Titan
Biodexa Pharmaceuticals (BDRX) flags going-concern doubts amid ongoing losses - Stock Titan
Biodexa (NASDAQ: BDRX) grows pipeline but warns on 2026 funding needs - stocktitan.net
Preliminary Results for the Year Ended 31 December 2025 - GlobeNewswire
Biodexa releases audited preliminary 2025 results for investors - Stock Titan
Biodexa partners with Tanner Pharma for FAP drug early access By Investing.com - Investing.com Australia
Biodexa Launches Global Early Access Program for eRapa for - GlobeNewswire
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group - markets.businessinsider.com
Biodexa partners with Tanner Pharma for FAP drug early access - Investing.com
Biodexa (NASDAQ: BDRX) director reports detailed stock option holdings - stocktitan.net
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules By Investing.com - Investing.com Australia
Biodexa Pharmaceuticals announces ADR ratio change - MSN
Biodexa Pharmaceuticals Announces Reverse ADR Split to Support Nasdaq Compliance - tipranks.com
Biodexa Pharmaceuticals (BDRX) Announces ADR Ratio Change - GuruFocus
Biodexa Pharmaceuticals changes ADR ratio to meet Nasdaq rules - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change to Comply with Nasdaq Minimum Bid Price Requirement - Quiver Quantitative
Reverse ADR split at Biodexa (Nasdaq: BDRX) targets Nasdaq $1 bid rule - Stock Titan
ADR Ratio Change - Bitget
Biodexa Pharmaceuticals (NASDAQ: BDRX) director lists stock option position - Stock Titan
Biodexa (NASDAQ: BDRX) CEO lists detailed stock option holdings - Stock Titan
Biodexa Pharmaceuticals (NASDAQ: BDRX) director details ADS option stake - Stock Titan
Biodexa (BDRX) CFO details multi-year stock option grants - Stock Titan
Biodexa Pharmaceuticals (BDRX) director Simon Turton reports initial equity holdings - Stock Titan
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients - ChartMill
New U.S. group for those facing near-100% colon cancer risk, backed by Biodexa - Stock Titan
Biodexa Pharmaceuticals Plc Adr (BDRX) 財務データ
収益
当期純利益
現金流量
EPS
0.29%
0.00%
大文字化:
|
ボリューム (24 時間):